| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f0ebf4d33fadb831dfca40056e75d5c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0085
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6806
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 |
| filingDate |
2014-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92f7f464d7644c00087f9daa5c0fcdb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ccf8a47e3238736dbbcd63c1214189e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7961ff89c8f5d4098da3d126f3f1189
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8abb110a4ccbd26af0965a8f08162a83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f0783cb94accf32f6b3948c867deaf3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63f194a9ea917df9f9134f8310962353 |
| publicationDate |
2014-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2014204814-A1 |
| titleOfInvention |
Treatment of brain cancer with oncolytic adenovirus |
| abstract |
The present disclosure involves compositions and methods for treating brain cancers having mutations in the retinoblastoma (Rb) pathway using an oncolytic adenovirus comprising an alteration in the Rb binding site of El A, and a targeting motif inserted in the Ad fiber protein. The adenovirus is able to kill the tumor cells without harming cells with a wild-type retinoblastoma pathway. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11065285-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020047345-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11155599-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021024207-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10238698-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022034506-A1 |
| priorityDate |
2013-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |